Sy Mukherjee

366 articles by Sy Mukherjee

• Sanofi cashes in $245M review voucher to leapfrog Novo in crucial diabetes combo race

  Feb. 24, 2016

• Jury orders J&J to pay patient's family $72M in talcum powder-ovarian cancer case

  Feb. 24, 2016

• Double whammy: Valeant stock hammered on Philidor accounting issues, CVS Jublia restrictions

  Feb. 23, 2016

• Bayer to name new CEO to replace chief exec who transformed firm: report

  Feb. 22, 2016

• Biotech pioneer Alfred Mann resigns as Executive Chairman of struggling MannKind

  Feb. 19, 2016

• Cipla snatches 1st US manufacturing plant as part of 'landmark acquisition'

  Feb. 18, 2016

• Chasing blockbusters: Does pharma need to change its success strategy?

  Feb. 18, 2016

• One Louisiana doc's made millions blowing the whistle on big pharma. Is that problematic?

  Feb. 18, 2016

• UPDATE: AstraZeneca & Daiichi rebuff Vermont governor's call to pull OIC Super Bowl ad

  Feb. 17, 2016

• Aegerion chopping 25% of its workforce in global reorg, eyes pipeline growth

  Feb. 12, 2016

• India's Ipca slammed by FDA for litany of severe data violations

  Feb. 11, 2016

• Report: Walgreens threatened to dissolve Theranos arrangement barring quick fixes

  Feb. 11, 2016

• After strong FDA panel backing, Celltrion & Pfizer's Remicade copycat could become 2nd US biosim

  Feb. 10, 2016

• Obama budget's $825 million NIH boost could hit big snags over funding structure

  Feb. 10, 2016

• In blow to Sanofi, UK's NICE reverses course & backs Amgen's PCSK9 med

  Feb. 9, 2016

• Update: After patient deaths, FDA puts CTI BioPharma's myelofibrosis on full clinical hold

  Feb. 8, 2016

• UPDATE: Feds give Theranos one more week to respond to damaging CMS inspection

  Feb. 5, 2016

• How top Valeant & Turing execs defended their drug prices to Congress on Thursday

  Feb. 5, 2016

• Liability: The big biosim legal scuffle the industry should be anticipating

  Feb. 4, 2016

• Martin Shkreli goes to Washington—and refuses to say anything to Congress

  Feb. 4, 2016

• Senators urge Obama to ramp up pressure against high drug prices

  Feb. 3, 2016

• With steady Q4 earnings in hand, Glaxo chief requests 3 years for more consumer unit profits

  Feb. 3, 2016

• 2016 sees its first US IPOs as biotechs Editas, BeiGene enter a turbulent market

  Feb. 3, 2016

• Pfizer's Q4 mixed bag spotlights its pipeline dilemma

  Feb. 2, 2016

• UK scientists win regulatory clearance to edit human embryo genes in CRISPR-Cas9 milestone

  Feb. 1, 2016

• Gilead chief Martin to step down from CEO role after 20 years

  Jan. 29, 2016

• Specialty injectables maker Sagent considering buyout with Cipla, Dr. Reddy's, others

  Jan. 28, 2016

• Massachusetts AG threatens Gilead with legal complaint over hep C drug prices

  Jan. 27, 2016

• Q4 earnings updates: Biogen beats on strong MS sales, no 'quick fix' on Alcon for Novartis

  Jan. 27, 2016

• Trump joins Clinton, Sanders, & Obama in endorsing Medicare drug price negotiations

  Jan. 27, 2016

• Sanofi EVP & former Obama admin official Suresh Kumar on the TPP, drug prices, & Dengue

  Jan. 26, 2016

• UPDATED: Feds to reportedly unveil new findings of 'serious deficiencies' at Theranos lab

  Jan. 25, 2016

• Walgreens CEO hops on the pricing critic train, says consumer Rx should be cheaper

  Jan. 22, 2016

• Cost control in the time of biopharma consolidation & globalization

  Jan. 21, 2016

• Pfizer reportedly mulling production expansion in Russia with Polysan

  Jan. 21, 2016

• Bombshell indictment accuses Glaxo scientists of stealing firm's trade secrets to sell in China

  Jan. 21, 2016

• After patient deaths, new Zafgen obesity med data revives approval hopes

  Jan. 21, 2016

• Shkreli & Valeant's interim CEO to face down Congress in pricing testimony next week

  Jan. 20, 2016

• NY strikes price cut, CVS distribution deal for Amphastar's heroin overdose antidote

  Jan. 20, 2016

• J&J to cut 3,000 jobs in major shakeup—is it a prelude to an acquisition?

  Jan. 19, 2016

• FDA harshly criticizes Sarepta's Duchenne drug just one day after rejecting BioMarin's

  Jan. 15, 2016

• Pfizer CEO: Our CAR-T development method could give us a leg up over Kite, Juno, Novartis

  Jan. 14, 2016

• JPM16 winds down: Valeant's pricing promise, J&J's small deal focus, & a murky biopharma outlook

  Jan. 14, 2016

• JPM16: An unprecedented cancer cure 'MoonShot,' Anthem threatens Express Scripts breakup

  Jan. 13, 2016

• More from JPM16: Glaxo talks potential spinoff, 'Pfallergan' addresses future breakup scenario

  Jan. 13, 2016

• JPM16 & BTS16: A dour start to biopharma's big week as stocks feel the pain

  Jan. 12, 2016

• Former Glaxo manager launches whistleblower suit over Nicoderm data

  Jan. 8, 2016

• 3 key biopharma manufacturing stories to keep an eye on in 2016

  Jan. 7, 2016

• J&J may sell off its Noramco manufacturing unit in $800 million deal

  Jan. 7, 2016

• Could an old Roche arthritis med become a pioneering PAH treatment?

  Jan. 7, 2016

• Lilly's 2016 outlook dogged by exchange rates, buoyed by pipeline

  Jan. 6, 2016

• Valeant names former CFO Schiller interim CEO as Pearson remains hospitalized

  Jan. 6, 2016

• Sanofi & struggling MannKind ditch collab agreement amid Afrezza inhaled insulin flop

  Jan. 5, 2016

• Clinton unveils plan to find Alzheimer's cure by 2025 with $20 billion in NIH funding

  Dec. 22, 2015

• UPDATE: Shkreli resigns post as Turing Pharma CEO, kicked out of KaloBios

  Dec. 21, 2015

• Defiant Shkreli hits back at feds, says arrest was driven by his price hikes

  Dec. 21, 2015

• UPDATED: House passes $1.1T spending bill with NIH boost, pediatric review voucher extension

  Dec. 18, 2015

• Why Martin Shkreli's arrest won't take the heat off the biopharma industry

  Dec. 18, 2015

• How biopharma and media are reacting to Shkreli's arrest

  Dec. 17, 2015

• Martin Shkreli arrested by FBI on securities fraud charges related to former firm

  Dec. 17, 2015

• Valeant notches big win with 20-year Walgreens distribution deal, but slashes earnings forecasts

  Dec. 16, 2015

• Shkreli's latest acquire-and-hike antics spotlight review voucher critics' biggest fears

  Dec. 15, 2015

• The new PCSK9 scorecard: Praluent favored by UnitedHealth, Repatha by CVS, both by Express Scripts

  Dec. 11, 2015

• Sprout CEO Cindy Whitehead heads for the exits amid lackluster Addyi launch

  Dec. 11, 2015

• UPDATE: FDA places complete hold on Zafgen obesity med trials after 2nd patient death

  Dec. 3, 2015

• REPORT: Key lawmakers own major stakes in biopharma, healthcare firms they oversee

  Dec. 1, 2015

• How pharma is trying to get patients to stay on their meds—and out of the hospital

  Nov. 30, 2015

• Will a defiant Northwest Bio shy away from a financial investigation by an FBI vet?

  Nov. 30, 2015

• So your biopharma got fined millions by the feds—Where does that money go?

  Nov. 25, 2015

• The 'Pfallergan' fallout: Reactions to—and questions for—the biggest healthcare deal of all time

  Nov. 24, 2015

• UPDATED: Pfizer, Allergan agree to historic $160 billion inversion merger

  Nov. 23, 2015

• Pfizer, Allergan reportedly prepping record $150B merger ahead of new inversion rules

  Nov. 19, 2015

• Senators grilled Obama's nominee for FDA chief. Here's how he responded

  Nov. 18, 2015

• Liver Meeting '15 wrapup: Battling more hep C genotypes, shortening treatment regimens

  Nov. 18, 2015

• Liver Meeting '15: AASLD calls out payers on HCV med coverage; WHO's plan to wipe out hep C & B by 2030

  Nov. 17, 2015

• Liver Meeting 2015: Merck combo shines for IV drug abusers, Genfit preps phase 3 for pioneering NASH med

  Nov. 16, 2015

• 3 charts that show how VC funding in life sciences reached all-time highs in Q3

  Nov. 13, 2015

• Perrigo shareholders handily reject Mylan's $26B hostile takeover bid

  Nov. 13, 2015

• Burdened with languishing Afrezza sales, MannKind sells off shares to Israeli bourse

  Nov. 11, 2015

• Judge: Valeant and Bill Ackman can't dodge Allergan investors' insider trading suit

  Nov. 11, 2015

• Outer space: The final frontier of biopharma R&D

  Nov. 11, 2015

• No 'purple pill' for Dr. Reddy's—court sides with AZ, blocks Nexium generic over coloration

  Nov. 10, 2015

• Under siege, Valeant chief insists short-term hits will give way to long-term gains

  Nov. 10, 2015

• Report: Amgen wants to get off the M&A sidelines, pursue $10 billion deal

  Nov. 9, 2015

• Feds: Medicaid programs restricting pricey hep C med access may be violating law

  Nov. 6, 2015

• Cellectis makes history as CAR-T therapy clears terminal leukemia in baby girl

  Nov. 6, 2015

• OxyContin gets political as Jeb Bush slams label expansion for kids, excess prescriptions

  Nov. 5, 2015

• House Dems launch drug pricing 'task force,' demand Turing & Valeant CEO subpoenas

  Nov. 4, 2015

• The next HIV breakthrough? Glaxo, J&J's long-acting shot as effective as 3-pill daily combo

  Nov. 3, 2015

• Valeant severs ties with controversial specialty pharma after mass PBM exodus

  Oct. 30, 2015

• UPDATE: Walgreens to snap up Rite Aid at 48% premium, forming drug store giant

  Oct. 27, 2015

• 3 earnings beats and a miss: Examining Pfizer, Merck, Bristol-Myers, and Novartis' Q3

  Oct. 27, 2015

• How Valeant tried to defend itself on Monday morning's investor call

  Oct. 26, 2015

• Armed with earnings beat, defiant Shire to persist in Baxalta bid

  Oct. 23, 2015

• What in the world is going on at Valeant? A guide to what we know so far

  Oct. 22, 2015

• Valeant trading at 52-week low on report alleging 'phantom pharmacies' & fake sales

  Oct. 21, 2015

• 23andMe relaunches expanded genetic tests after 2-year, FDA-mandated hiatus

  Oct. 21, 2015

• A bipartisan bashing: Rubio slams drug prices, pharma's 'pure profiteering'

  Oct. 20, 2015

• Massive gov't study promotes smaller drug doses, more talk therapy for schizophrenia

  Oct. 20, 2015

• Feds investigating Valeant's drug pricing, patient assistance programs

  Oct. 15, 2015

• The curious case of Zafgen's stock and a phase 3 patient death

  Oct. 15, 2015

• The 'best-performing' CEO in the world is a pharma chief

  Oct. 14, 2015

• Lilly faces crushing setback as it's forced to abandon lead heart drug

  Oct. 12, 2015

• Pharma CEOs head to WH to hear Obama's TPP pitch; Clinton comes out against trade deal

  Oct. 8, 2015

• Pharma giants join forces to squash CA drug price cap initiative

  Oct. 8, 2015

• Express Scripts to cover both Sanofi/Regeneron's & Amgen's PCSK9 meds

  Oct. 7, 2015

• TPP trade deal reached, BIO & PhRMA unhappy with drug patent compromise

  Oct. 5, 2015

• 10 top trends driving the biopharma industry today

  Oct. 1, 2015

• Another kidney cancer hopeful: Exelixis med reduces tumor progression, death risk

  Sept. 29, 2015

• BIO kicks out Shkreli, Turing Pharma in wake of Daraprim price debacle

  Sept. 24, 2015

• Is Martin Shkreli biopharma's unwitting whistleblower?

  Sept. 23, 2015

• Perrigo gets personal, urges shareholders to reject Mylan hostile bid & keep shares

  Sept. 17, 2015

• UPDATE: Obama nominates Robert Califf as next FDA commissioner

  Sept. 16, 2015

• ICER: Novartis' expected heart failure mega-blockbuster overpriced just 17%

  Sept. 15, 2015

• Pill of the future? FDA to review first-ever 'digital medication' application

  Sept. 11, 2015

• Novartis to join forces with Google, launch human tests for 'smart' contacts

  Sept. 8, 2015

• US biosimilar era officially dawns as Novartis' Zarxio launches Thursday

  Sept. 2, 2015

• Google life sci strikes another big pharma research collab, this time with Sanofi

  Aug. 31, 2015

• Pricing & dosing controversies: What to expect after Amgen's new PCSK9 approval

  Aug. 28, 2015

• UPDATE: Biotech, pharma stocks rally after a roller coaster Monday

  Aug. 25, 2015

• Valeant strikes $1B deal to snag women's libido drug maker Sprout

  Aug. 20, 2015

• UPDATE: Sprout plots hiring binge after controversial female libido drug approval

  Aug. 18, 2015

• Juno loss widens in Q2 as R&D costs skyrocket

  Aug. 14, 2015

• Roche snaps up diagnostics firm for $425M as part of antibiotics refocus

  Aug. 14, 2015

• To reinflate lung portfolio, Glaxo needs Breo to shine where Advair failed

  Aug. 14, 2015

• Tracking Parkinson's patients for a drug trial? Roche has an app for that

  Aug. 14, 2015

• Avalanche shares continute to fall off a cliff as company ditches eye drug trial

  Aug. 14, 2015

• Will Dodd-Frank's CEO-worker pay ratio rule put the heat on pharma chiefs?

  Aug. 13, 2015

• Cancer Letter journo fights Amgen subpoena in shareholder suit

  Aug. 13, 2015

• Soaring drug costs at heart of military funding scuffle

  Aug. 13, 2015

• AbbVie, Genentech to seek US approval of potential blockbuster leukemia med

  Aug. 12, 2015

• Clovis & Genentech team up to test out a promising lung cancer combo

  Aug. 12, 2015

• FDA chastizes Duchesnay, Kim Kardashian over drug promo posts

  Aug. 12, 2015

• UPDATE: Glaxo to reopen NC plant this weekend after Legionnaires' scare

  Aug. 12, 2015

• Bill Gates gets in on the CRISPR/Cas9 frenzy with Editas backing

  Aug. 11, 2015

• UK's Mallinckrodt to buy US immunotherapy firm Therakos for $1.33B

  Aug. 11, 2015

• What will Google's huge 'Alphabet' restructure mean for its life sci ambitions?

  Aug. 11, 2015

• FDA loses off-label marketing suit against Amarin in major setback

  Aug. 10, 2015

• CVS to adopt 'wait and see' approach on PCSK9 cholesterol meds

  Aug. 10, 2015

• Shire offers $30B for Baxalta with sights on becoming rare disease titan

  Aug. 4, 2015

• Finally: Merck Ebola vax triumphs in phase III trial, overcoming logistical nightmare

  July 31, 2015

• Sanofi surprises in Q2 with strong MS sales, AZ slides on generic competition

  July 30, 2015

• Blockbuster Friday: Sanofi/Regeneron wins first US approval of PCSK9 cholesterol med

  July 24, 2015

• 3 major earnings updates: Bristol-Myers, Lilly, & Valeant all soar past expectations

  July 23, 2015

• A mixed bag: Biogen's & Lilly's hotly anticipated Alzheimer's data are inconclusive

  July 22, 2015

• House overwhelmingly votes to pass 21st Century Cures FDA reform bill

  July 10, 2015

• Novartis set to redraw the heart failure map with rapid approval of game-changer Entresto

  July 8, 2015

• Teva plans to hike Mylan bid by $2B to $43 billion this week: report

  July 7, 2015

• AstraZeneca, Teva to shell out $54M to settle Medicaid rebate underpayment claims

  July 7, 2015

• Iowa State scientist sentenced to 57 months in prison for HIV vax trial fraud

  July 2, 2015

• Supreme Court OKs use of controversial drug for US executions

  June 29, 2015

• With new Cosentyx data, Novartis slated to nab huge psoriasis market share

  June 29, 2015

• How Titan Pharma wants to make implants the drug delivery systems of the future

  June 25, 2015

• EXCLUSIVE: An interview with Sanofi's president of North American pharma

  June 24, 2015

• A MedImmune SVP dishes on nanomed, antibiotic resistance, & his advice for biopharma

  June 23, 2015

• Biopharma titans Kite, Bluebird join forces to tackle HPV cancers

  June 22, 2015

• BIO2015: The next 'plastics' of biotech and a barreling towards another record M&A year

  June 19, 2015

• Your BIO2015 guide: Biotech in space, a BIO name change and more

  June 18, 2015

• BIO2015: Vertex founder tells VCs to cool it on the science, stick to investment

  June 17, 2015

• Pharma's Fortune 500: The top ranked companies of 2015

  June 12, 2015

• Biogen, Shire, Allergan top list of 'greenest' corporations in the world

  June 11, 2015

• Amgen PCSK9 drug gets FDA staff rec, but panelists express concerns

  June 10, 2015

• Biosim war heats up as Merck's Remicade & Enbrel biosimilars bag major wins in RA

  June 10, 2015

• Another day, another barb: Teva calls Mylan's anti-takeover tactics 'desperate'

  June 9, 2015

• Titan Pharma's opioid addiction implant shows promise in phase III

  June 8, 2015

• How VC funding for biotech has fundamentally changed—and what it means for the industry

  June 3, 2015

• A final ASCO15 roundup: Docs slam prices for meds, ImmunoGen eyes redemption, Puma gets hammered

  June 2, 2015

• ASCO15: BMS' new standard for melanoma, Celldex's brain cancer vax, Clovis' ovarian cancer win

  May 31, 2015

• Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J

  May 30, 2015

• 3 major trends driving layoffs in biotech and pharma

  May 27, 2015

• Bluebird shares more data on its breakthrough gene therapy trials, and it continues to impress

  May 22, 2015

• House committee unanimously passes 21st Century Cures FDA reform bill

  May 21, 2015

• CVS to buy nursing home pharmacy Omnicare for $12.7 billion

  May 21, 2015

• Top FDA official: Listing detailed drug risks in pharma TV ads a 'waste of time'

  May 20, 2015

• Bluebird cuts deal with regulators, plots path to first-ever US gene therapy approval

  May 19, 2015

• Industry, advocate pressure helps revive key 21st Century Cures exclusivity incentives

  May 14, 2015

• UPDATE: Takeda threatens to break off Orexigen collab after Contrave data drama

  May 13, 2015

• Mylan chairman thinks Teva a bad cultural fit, would consider buying it anyway

  May 11, 2015

• Glaxo's new chairman signals support for embattled CEO Witty

  May 8, 2015

• Alexion to buy Synageva BioPharma in $8.4B rare disease megadeal

  May 6, 2015

• IBM's Watson Health to collab with 14 major oncology centers on cancer genomics

  May 6, 2015

• Pfizer animal med spinoff Zoetis could axe 25% of workforce after Ackman pressure

  May 5, 2015

• The 10 brand name drugs that cost Medicare Part D the most money in 2013

  April 30, 2015

• Inside one pharma's mission to make a transdermal patch for insulin, vaccines, and more

  April 30, 2015

• 4 big changes you need to know about the latest draft of 21st Century Cures

  April 30, 2015

• 3 key lessons industry leaders have learned from the latest Ebola crisis

  April 28, 2015

• How Virginia's governor plans to get his state into the life sciences game

  April 24, 2015

• Strong cancer drug sales drive Roche to an impressive Q1

  April 22, 2015

• Merck CEO Kenneth Frazier elected as PhRMA's next board chairman

  April 16, 2015

• Regeneron CEO to join NY Gov. Cuomo on historic Cuba trade trip

  April 16, 2015

• IBM joins forces with J&J, Medtronic, Apple in ambitious clinical research data pact

  April 15, 2015

• UPDATE: FDA says key AstraZeneca diabetes drug may 'significantly' increase death risk

  April 13, 2015

• Sanofi digs in heels, won't discount Lantus insulin successor Toujeo

  April 13, 2015

• Pharmacy giant Walgreens to shutter 200 US stores by 2017

  April 10, 2015

• 3rd largest Medicaid program didn't spend a dime on Sovaldi due to high cost

  April 9, 2015

• UPDATE: Mylan offers $29 billion to buy Perrigo, create generics powerhouse

  April 8, 2015

• Bristol-Myers sends uniQure soaring with $1B cardiovascular gene therapy deal

  April 6, 2015

• 4 big biopharma deals we might see in 2015

  April 6, 2015

• Could NYC become the next big biotech hub?

  April 2, 2015

• Pfizer to immediately cease vaccine sales in China over licensing spat

  April 2, 2015

• Takeda offers $2.2 billion in massive Actos class action settlement proposal

  April 1, 2015

• Sarepta CEO resigns abruptly amid tense relationship with FDA

  April 1, 2015

• The M&A train rolls on: Teva to buy American CNS drug maker for $3.2B

  March 30, 2015

• Obama administration releases first major long-term 'superbug' response plan

  March 27, 2015

• Lilly slams Indiana's new 'religious freedom' law

  March 27, 2015

• Gilead CEO John Martin's true compensation could be $600 million

  March 25, 2015

• Is Amgen's genomic map of Iceland the ghost of personalized med's future?

  March 25, 2015

• ICYMI: Why 2015 is the year of the biopharma blockbuster (with charts)

  March 24, 2015

• Biogen Idec rebrands as Biogen, bets big on neurodegenerative pipeline

  March 23, 2015

• Biogen soars as Alzheimer's drug data shows sharp slowdown in cognitive decline

  March 20, 2015

• FDA panel says Glaxo asthma drug isn't proven safe for teens

  March 20, 2015

• Amgen, Sanofi PCSK9 drugs shown to cut CVD risk in half

  March 16, 2015

• UPDATE: Valeant successfully fends off Endo, seals deal with Salix

  March 16, 2015

• A steady March of job cuts: Amgen to axe 40% of remaining Onyx staff

  March 10, 2015

• FDA New Drugs chief: Orexigen's sunny Contrave heart data 'likely false'

  March 6, 2015

• AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline

  March 5, 2015

• SEC to pharma: Don't get cute with disclosing FDA dealings to investors

  March 4, 2015

• FDA approves Actavis' QIDP-designated antibiotic combo

  Feb. 26, 2015

• UPDATE: Sanofi's likely blockbuster insulin Toujeo wins FDA approval

  Feb. 25, 2015

• Game time: Remicade biosims from Celltrion, Hospira launch in big EU markets

  Feb. 25, 2015

• Pfizer planning more layoffs in R&D

  Feb. 24, 2015

• Engineering cures for metabolic diseases: A conversation with a Stanford biochemist

  Feb. 24, 2015

• In historic reversal, FDA approves 23andMe genetic test for Bloom Syndrome

  Feb. 20, 2015

• UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout

  Feb. 20, 2015

• UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO

  Feb. 19, 2015

• 3 charts that show why 2014 was a record year for US orphan drugs

  Feb. 17, 2015

• Eisai, Pfizer, and Novartis meds get FDA love over the long weekend

  Feb. 13, 2015

• Hospira CEO's golden parachute for Pfizer deal: $80 million

  Feb. 12, 2015

• UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg

  Feb. 11, 2015

• Citi analyst: Humira biosims will hurt AbbVie sales more than you think

  Feb. 11, 2015

• Gilead to open London HQ, double UK workforce

  Feb. 10, 2015

• A faster cure? Achillion med mixed with Sovaldi clears hep C in just 6 weeks

  Feb. 9, 2015

• Sanofi: Q4 earnings beat forecast, new CEO to be named by end of Q1 2015

  Feb. 5, 2015

• UPDATED: FDA chief Hamburg to resign at end of March

  Feb. 5, 2015

• Earnings roundup: Merck tops expectations, steady GSK rises on ViiV IPO talk

  Feb. 4, 2015

• UPDATE: Why Gilead's shares are tumbling despite stellar Q4 earnings

  Feb. 3, 2015

• UK first in world to legalize '3-person DNA' babies to curb genetic disorders

  Feb. 3, 2015

• Sanofi finally launches Afrezza inhaled insulin in the US

  Feb. 3, 2015

• UPDATE: Obama budget proposes historic, direct Medicare drug price negotiations

  Feb. 2, 2015

• Obama to unveil $215M personalized medicine, million-person DNA sequencing project

  Jan. 30, 2015

• Greed is misunderstood? Tackling biopharma's pricing image problem

  Jan. 29, 2015

• 4 things you need to know about the sweeping FDA reform bill Congress just proposed

  Jan. 28, 2015

• Expiring patents, surging dollar dog BMS, Pfizer, & Novartis earnings

  Jan. 27, 2015

• Sanofi/Regeneron off to the races with priority review of cholesterol game-changer

  Jan. 26, 2015

• UPDATED: Sen. Elizabeth Warren proposes big new pharma fines to fund NIH research

  Jan. 22, 2015

• REPORT: Takeda COO Weber approached for vacant Sanofi CEO post

  Jan. 22, 2015

• FDA approves likely Novartis psoriasis blockbuster Cosentyx

  Jan. 21, 2015

• Obama proposes genetic 'Precision Medicine Initiative' at State of the Union

  Jan. 21, 2015

• BMS' new chief: COO Giovanni Caforio to replace CEO Andreotti in May

  Jan. 20, 2015

• 4 key industry trends that will impact biopharma in 2015

  Jan. 19, 2015

• J&J gets $115 million cash to speed Ebola vax development

  Jan. 16, 2015

• Sarepta fights back, Sanofi/BI partner, and more from the last day of JPM15

  Jan. 15, 2015

• EXCLUSIVE: An interview with Sanofi EVP Pascale Witz at JPM15

  Jan. 14, 2015

• AbbVie's Humira/hep C plans, bluebird bio, NIH funding, and even more from JPM15

  Jan. 14, 2015

• Express Scripts, PCSK9s, Gilead, and Shire: More from JPM15 and BTS15

  Jan. 13, 2015

• BioMarin, Merck, and Sanofi: The biggest news so far from 'JPM15' and 'BTS15'

  Jan. 13, 2015

• Genentech and Google-backed 23andMe strike Parkinson's research deal

  Jan. 7, 2015

• Salix CEO Logan becomes second C-suite casualty of inventory spat

  Jan. 6, 2015

• CVS to favor Gilead hep C meds over AbbVie's, setting up showdown with Express Scripts

  Jan. 5, 2015

• Promising late-stage trial bodes well for Cempra's next-gen antibiotic

  Jan. 5, 2015

• Novo searching for successor to CEO Sørensen, who has big shoes to fill

  Dec. 29, 2014

• UPDATED: FDA grants BMS's novel Opdivo accelerated approval for advanced melanoma

  Dec. 22, 2014

• UPDATED: Express Scripts snubs Gilead, will only offer AbbVie's new hep C pill

  Dec. 19, 2014

• CVS Health: Harvoni being prescribed at 2.5 times the rate of Sovaldi

  Dec. 19, 2014

• The 14 drugs most likely to top global pharma sales in 2015 and 2020

  Dec. 18, 2014

• Historic: FDA approves first-ever system to cut blood transfusion infections

  Dec. 17, 2014

• The 11 biggest drug launches to watch in 2015

  Dec. 15, 2014

• ICYMI: 3 charts that show why 2014 was a milestone year for US novel drug approvals

  Dec. 12, 2014

• Merck, NewLink Ebola vax trial suspended over joint pain complaints

  Dec. 11, 2014

• Indian company first to the finish line with historic Humira biosimilar

  Dec. 10, 2014

• CEO of growing biopharma CRO killed in Maryland small jet crash

  Dec. 9, 2014

• UPDATED: Jury sides with AZ in crucial pay-for-delay case over Nexium generics

  Dec. 5, 2014

• CDC pushing Tamiflu, Relenza because current flu strain doesn't match vaccine

  Dec. 4, 2014

• Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg

  Dec. 3, 2014

• BioMarin makes $840M gamble, buys Prosensa and its orphan drugs

  Nov. 24, 2014

• The 14 best-performing CEOs in biotech and pharma

  Nov. 21, 2014

• US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark

  Nov. 20, 2014

• HHS scraps regulations for 340B drug pricing program

  Nov. 18, 2014

• UPDATED: Actavis buys Allergan for $66 billion

  Nov. 17, 2014

• Cancer immunotherapy specialist Juno Therapeutics files for IPO

  Nov. 17, 2014

• Activist investor Bill Ackman's $2 billion fallback plan for Valeant

  Nov. 12, 2014

• Specter of antitrust charges looms as Justice Department probes generic price hikes

  Nov. 11, 2014

• Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]

  Nov. 11, 2014

• Advocates slam protracted UK negotiations over Novartis meningitis B vaccine

  Nov. 10, 2014

• ICYMI: The top 18 pharma-backed candidates who won in last week's elections

  Nov. 6, 2014

• AstraZeneca lifts 2014 forecast, but how will it deal with Nexium patent expiration?

  Nov. 6, 2014

• Could the Sanofi CEO's firing doom a $150 million inhaled insulin deal?

  Nov. 4, 2014

• RAND study: Biosimilars could save US $44 billion in 10 years

  Nov. 4, 2014

• Uh-oh: 2/3 of UK docs defying new statin guidelines

  Nov. 3, 2014

• ICYMI: 5 movies where biopharma goes horribly wrong

  Oct. 31, 2014

• AZ scores FDA approval of once-daily diabetes fixed-dose combo pill

  Oct. 30, 2014

• Merck beats Q3 forecasts, scores another Keytruda 'breakthrough'

  Oct. 27, 2014

• BMS beats analyst expectations on strong cancer, RA drug sales

  Oct. 24, 2014

• Lilly's Q3 profits drop sharply, hammered by patent expirations

  Oct. 23, 2014

• The $5.3B Mylan-Abbott inversion deal won't go the way of AbbVie-Shire

  Oct. 22, 2014

• UPDATED: GSK, NewLink Ebola vaccine trials could launch this January in Africa

  Oct. 21, 2014

• Actelion chief says it's time for pharma to ditch tax-inversion mergers

  Oct. 21, 2014

• Sorry, Pfizer: FDA won't nix black box suicide warning for Chantix

  Oct. 17, 2014

• Game on: Amgen sues Sanofi, Regeneron over PCSK9 cholesterol drug patent

  Oct. 17, 2014

• AbbVie-Shire deal effectively dead in the water

  Oct. 16, 2014

• UPDATED: Mark Zuckerberg announces $25 million CDC donation to fight Ebola

  Oct. 14, 2014

• Report: 6 US Ranbaxy execs head for the exits before Sun Pharma merger

  Oct. 13, 2014

• Pfizer nabs FDA priority review for potential breast cancer blockbuster

  Oct. 13, 2014

• AZ faces Texas lawsuit over bribery, improper marketing of antipsychotic drug

  Oct. 13, 2014

• UPDATED: On to the next one: FDA approves new Gilead hep C combo pill Harvoni

  Oct. 10, 2014

• PhRMA sues feds, again, over controversial hospital orphan drug discount rule

  Oct. 10, 2014

• UPDATED: Chimerix plummets on news of Dallas Ebola patient's death

  Oct. 8, 2014

• Is the UK's NHS about to snub Sovaldi?

  Oct. 8, 2014

• BMS unexpectedly pulls application for hep C drug

  Oct. 7, 2014

• The revolution will be personalized: An interview with two Stanford geneticists

  Oct. 1, 2014

• Zogenix files for addiction-fighting version of controversial pain pill Zohydro

  Oct. 1, 2014

• Tekmira stock opens big on news of first US Ebola case

  Oct. 1, 2014

• FDA rejects anti-addiction rule that would ban crushable Ritalin, opiates

  Sept. 30, 2014

• Roche's Perjeta 'unprecedented' in extending breast cancer patients' lives

  Sept. 29, 2014

• Federal judge dismisses racketeering charges against AbbVie, Abbott

  Sept. 26, 2014

• US doc treated with Tekmira Ebola drug declared virus free

  Sept. 25, 2014

• FDA to review Otsuka and Lundbeck's potential schizophrenia game changer

  Sept. 25, 2014

• GSK names Royal Bank of Scotland head its next chairman

  Sept. 25, 2014

• Tax-inversion hopefuls balk at new White House plans to curb deals

  Sept. 23, 2014

• UPDATED: Tekmira tempers expectations as regulators clear Ebola drug for emergency use

  Sept. 23, 2014

• Auxilium: Endo's $2.2B takeover bid 'significantly undervalues' company

  Sept. 22, 2014

• UPDATED: GSK found guilty of bribery in China, fined record $489 million

  Sept. 19, 2014

• Lilly enters crowded diabetes field as FDA approves once-weekly Trulicity

  Sept. 19, 2014

• Instant pleasure: Vivus ED pill wins faster-acting 'on demand' label

  Sept. 18, 2014

• UPDATED: Report: Sovaldi dropout rate 4 times higher than in trials

  Sept. 17, 2014

• Gilead to allow Indian generics of pricey Sovaldi in developing nations

  Sept. 15, 2014

• Justice Department to seek contempt charges against Bayer

  Sept. 12, 2014

• Google's Calico pens development deal for Parkinson's, ALS-fighting compound

  Sept. 11, 2014

• FDA approves controversial weight loss pill Contrave

  Sept. 11, 2014

• Sanofi wants kids to game their way to diabetes control

  Sept. 10, 2014

• FDA narrowly rejects Actavis' blood pressure combo

  Sept. 10, 2014

• GSK, Gilead's pulmonary hypertension combo smashes goals in phase III trial

  Sept. 8, 2014

• Study: GSK Ebola vaccine effective, requires booster shot

  Sept. 8, 2014

• Pharmacist tied to tainted steroids, meningitis outbreak case arrested at airport

  Sept. 4, 2014

• Report: AZ-White House phone calls set off DC's tax-inversion backlash

  Sept. 4, 2014

• Google's Calico, AbbVie strike $1.5 billion R&D pact to fight age-related diseases

  Sept. 3, 2014

• Feds ink $25 million contract with Ebola drug maker Mapp Biopharma

  Sept. 3, 2014

• Bayer to finally bring world famous 'hangover cure' Berocca to US

  Sept. 2, 2014

• ZMapp saves Ebola-infected monkeys in 'monumental achievement'

  Aug. 29, 2014

• FDA OKs spinal cord injury stem cell trial for Asterias

  Aug. 28, 2014

• GSK's Ebola vaccine gets FDA go-ahead for phase I human trials

  Aug. 27, 2014

• Roche to buy CA-based biotech InterMune in $8.3 billion deal

  Aug. 25, 2014

• Medtronic execs, shareholders lock horns over tax-inversion deal

  Aug. 22, 2014

• The 4 pharma companies with the highest profit margins [Infographic]

  Aug. 22, 2014

• Hospira wins temporary restraining order against Precedex generics

  Aug. 20, 2014

• 1000s of companies revolt against Obamacare medical device tax

  Aug. 20, 2014

• 'Ice Bucket Challenge' defies skeptics, raises $22.9M for ALS research

  Aug. 19, 2014

• Hackers behind CHS data breach may have been targeting intellectual property

  Aug. 18, 2014

• FDA green lights Biogen MS drug

  Aug. 18, 2014

• Allergan names 30-year company vet next CFO amid Valeant chaos

  Aug. 18, 2014

• Black box warnings and drug market withdrawals, by the numbers

  Aug. 15, 2014

• UPDATED: FDA issues consumer warning on fake Ebola drugs

  Aug. 15, 2014

• Feds to investigate Valeant, Bill Ackman's Allergan takeover bid

  Aug. 14, 2014

• Merck sleeping pill Belsomra gets FDA approval

  Aug. 13, 2014

• UPDATED: WHO endorses experimental treatments for Ebola patients

  Aug. 12, 2014

• All gone for now: Ebola drug ZMapp supply exhausted

  Aug. 12, 2014

• GSK slapped with another bribery allegation

  Aug. 12, 2014

• Sanofi nabs rights to MannKind's inhaled insulin with $150 million deal

  Aug. 11, 2014

• WHO panel to debate ZMapp, ethics of experimental Ebola treatments

  Aug. 11, 2014

• GSK eases expectations on Ebola vaccine: 'Long, complex process'

  Aug. 11, 2014

• Chinese authorities imprison GSK sex tape investigator, wife

  Aug. 8, 2014

• Walgreens to buck tax-inversion trend, remain in Chicago after merger

  Aug. 6, 2014

• Allergan files federal lawsuit against Valeant, Pershing Square

  Aug. 1, 2014

• FDA unveils first-ever plans to regulate genetic diagnostic testing

  Aug. 1, 2014

• WHO plans $100 million emergency response as Ebola deaths top 700

  July 31, 2014

• President Obama slams tax-inversion mergers: 'An unpatriotic tax loophole'

  July 24, 2014